Sanofi Walks Away From Plavix Provincial Tender In China
This article was originally published in PharmAsia News
Despite expected pricing pressure, the depth of cuts from China’s closely watched provincial tenders for newly added essential drugs still bring out surprises, and even walkaways, as reference pricing remains a threat.
You may also be interested in...
A major European business group in China is encouraged by recent signals of further policy reforms, but says in a new report it would like to see further progress on drug and device tenders, the lifting of indirect competition restrictions, and full implementation of the central push for a level playing field for foreign firms.
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.
Increasingly looking to China to commercialize their latest therapies, multinationals may be leaping into unknown waters to navigate an intellectual property judiciary and administrative maze, in a country where some copy drugs have been approved before patent expiry. With a government trying to balance innovation and access, two recent rulings involving AstraZeneca shed rare light onto China’s protections for innovation, with advisors pointing to challenges and success factors.